Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GLS | O94925 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8046529 | 0.96 | ALDH1A1 (0.58) | ALDH1A1TSHRPOLBNPSR1CYP2C9 | |
| SCHEMBL8034034 | 0.94 | ALDH1A1 (0.61) | ALDH1A1TSHRPOLBNPSR1CYP2C9 | |
| SCHEMBL8045337 | 0.94 | ALDH1A1 (0.61) | ALDH1A1TSHRPOLBNPSR1CYP2C9 | |
| SCHEMBL14557094 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBNPSR1GLS | |
| SCHEMBL10404416 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRPOLBGLSKDM4E | |
| SCHEMBL6406054 | 0.78 | ALDH1A1 (0.69) | ALDH1A1TSHRPOLBNPSR1CYP2C9 | |
| SCHEMBL2212268 | 0.78 | — | — | |
| SCHEMBL5654025 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRPOLBNPSR1GLS | |
| SCHEMBL6553986 | 0.76 | ALDH1A1 (0.73) | ALDH1A1TSHRPOLBNPSR1CYP2C9 | |
| SCHEMBL22368217 | 0.76 | ALDH1A1 (0.73) | ALDH1A1TSHRPOLBNPSR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4172197-A | BACTERICIDES | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1979-10-23 | — | — | US | claimed |
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2037928-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | Amgen Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | disclosed |
| US-4245033-A | AN ORGANIC SILVER SALT, A HALIDE AND A SULFUR COMPOUND EXPOSED TO FORM A SILVER IMAGE OF HIGH CONTRAST AND STABILITY | CANON KABUSHIKI KAISHA (JP) | 1981-01-13 | — | — | US | disclosed |
| US-4016159-A | BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3968226-A | 3-Heterocyclic thiomethylcephalosporins as antibacterial agents | SMITHKLINE CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
| US-3962232-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | ALDH1A1 2876/4885TSHR 2835/4885POLB 2704/4885 |
| US-20080096900-A1 | Methods for treating atherosclerosis | LCAT, PCSK9, CETP | ALDH1A1 2876/4885TSHR 2835/4885POLB 2704/4885 |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | ALDH1A1 2876/4885TSHR 2835/4885POLB 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.